NUCC-390
Based on 6 publication(s) in Google Scholar
NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.01%
- CAS No.: 1060524-97-1
- Formule: C23H33N5O
- Masse moléculaire:395.54
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Chemokine Compound Library
HY-L132
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Extracellular Vesicles (EVs) Compound Library
HY-L168
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) NUCC-390
More- Proc Natl Acad Sci U S A. 2024 Dec 24;121(52):e2416909121. [Abstract]
- Int Immunopharmacol. 2026 Mar 1:172:116227. [Abstract]
- Int Immunopharmacol. 2024 Nov 30:144:113707. [Abstract]
- Microsc Microanal. 2025 Mar 17;31(2):ozaf011. [Abstract]
- Neurosci Res. 2023 Jun:191:38-47. [Abstract]
- Arab J Gastroenterol. 2024 Feb;25(1):28-36. [Abstract]
Activité biologique
|
CXCR4 |
NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100[1].NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors[1].NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1].NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C8161 cells
-
Concentration:10 μM
-
Incubation Time:Pre-treated 30 mins
-
Result:Increased the level of pERK.
-
Cell Line:Cerebellar granule neurons (CGNs)
-
Concentration:0 μM; 0.0625 μM; 0.25 μM; 1.25 μM
-
Incubation Time:24 hours
-
Result:Stimulated axonal growth via CXCR4.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six to eight-week-old CD1 mice[2]
-
Dosage:3.2 mg/kg
-
Administration:Hind limb injection; twice daily; 3 days
-
Result:Promoted functional and anatomical recovery of the NMJ.
Chemical Information
-
CAS No. 1060524-97-1
-
Appearance Solid
-
Masse moléculaire 395.54
-
Formule C23H33N5O
-
Color Light brown to brown
-
SMILES
O=C(N1CCCCC1)C2=NN(CCC)C3=C2CC(NCCC4=CC=NC=C4)CC3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc, and the immune checkpoint PD-L1 pathways. [Abstract]2024 Dec 24;121(52):e2416909121. PMID: 39689179 -
Int Immunopharmacol
Astragalin alleviates neuroinflammation in LPS-injured HT22 cells and CFA mice by regulating neuronal excitability and autophagy via CXCR4-Beclin1/VPS34 axis. [Abstract]2026 Mar 1:172:116227. PMID: 41548438 -
Int Immunopharmacol
Isoferulic acid regulates CXCL12/CXCR4-mediated apoptosis and autophagy in podocyte and mice with STZ-induced diabetic nephropathy. [Abstract]2024 Nov 30:144:113707. PMID: 39616856 -
Microsc Microanal
2025 Mar 17;31(2):ozaf011. PMID: 40095909 -
Neurosci Res
CXCR4 signaling regulates repair Schwann cell infiltration into the spinal cord after spinal cord injury in mice. [Abstract]2023 Jun:191:38-47. PMID: 36592826 -
Arab J Gastroenterol
C-X-C motif chemokine receptor 4 inhibition promotes the effect of plantamajoside in hepatocellular carcinoma. [Abstract]2024 Feb;25(1):28-36. PMID: 38220479
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Mishra RK, et al. Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists.Sci Rep. 2016 Jul 26;6:30155. [Content Brief]
[2]. Negro S, et al. An Agonist of the CXCR4 Receptor Strongly Promotes Regeneration of Degenerated Motor Axon Terminals.Cells. 2019 Sep 30;8(10). pii: E1183. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
NUCC-390 Related Classifications
HY-111793 Related Classifications
Powered by Bioz